Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's all about the progress of the science! Don't let anybody tell you anything else!
This is a good sign!
Good piont!
Anybody care to share their questions for the upcoming CC?
The bottom line is that a partner only cares about the science. We will know a lot more in a few months.
The manipulation of this stock is just so obvious from the mako lies to the crowing and whining of the shorts.
I agree with your sentiment and it's great to her from you again.
Agree the disconnect between share price and progress is huge as well the disconnect between the voices of the shareholders and the manipulators is huge as well.
Thanks for your thoughtful and we'll written response. I think the price will recover soon enough.
Looks like they gapped the open
I was trying to find that info today. It was a conference that is happening this week/weekend. It looks like the 10q usually comes out on the 2nd Monday of May. So hopefully we see something this coming Monday.
What you are asking for is not something they have provided or will provide at this piont.
Please show me were they are comparing "photos" before and after!
Primary Outcome Measures:
Proportion of participants achieving at least a 75% reduction from baseline in PASI score (PASI75) at Week 12 [ Time Frame: 12 Weeks ]
The Psoriasis Area and Severity Index (PASI) quantifies the severity of psoriasis based on lesion severity and the percent of body surface area affected. It is a composite assessment, across body regions, reflected in a single score: 0 (no disease) to 72 (maximal disease).
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 16 Weeks ]
Reporting of Adverse Events measurements, and reporting of adverse events.
Secondary Outcome Measures:
Proportion of subjects achieving a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline [ Time Frame: 16 Weeks ]
The static Physician Global Assessment reflects an overall severity of the erythema, induration and scaling across all psoriatic lesions on a 5-point scale, where 0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe.
PASI75 response at time points through Week 16 [ Time Frame: 16 Weeks ]
The Psoriasis Area and Severity Index (PASI) quantifies the severity of psoriasis based on lesion severity and the percent of body surface area affected. It is a composite assessment, across body regions, reflected in a single score: 0 (no disease) to 72 (maximal disease).
The actual and change from baseline in patient-reported itch severity score [ Time Frame: 16 weeks ]
The severity of itching due to psoriasis will be assessed on a horizontal numeric rating scale, anchored by the terms "No itching" (0) and "Worst possible itching" (10).
Assessment of patient-reported quality of life by the Dermatology Life Quality Index (DLQI) [ Time Frame: 16 Weeks ]
The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology questionnaire that assesses patient health-related quality of life in adult subjects with skin diseases such as psoriasis
Assessment of patient-reported quality of life by the Short Form-36 Health Survey (version 2, acute form) [ Time Frame: 12 Weeks ]
The SF-36 is a widely used general health status questionnaire that assesses 8 domains of functional health and well-being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions
Assessment of patient-reported quality of life by the Euro-Qol 5 Dimensions Health State Profile [ Time Frame: 12 Weeks ]
The EQ-5D is a generic instrument designed to assess a subject's general health status. The instrument consists of a questionnaire and a visual analog scale (VAS)
Assessment of Patient Satisfaction with Study Treatment (PSST) [ Time Frame: 12 Weeks ]
Overall patient satisfaction with study treatment will be assessed on a 7-point rating scale, with response options range from "very dissatisfied" to "very satisfied"
Plasma concentrations of Prurisol [ Time Frame: 4 Weeks ]
Measurement of Prurisol (abacavir glycolate) from a subset of subjects in the trial
Plasma concentrations of abacavir [ Time Frame: Timeframe: 4 weeks ]
Measurement of abacavir, a metabolite of Prurisol, from a subset of subjects in the trial
Because it's not part of the study!
Only B-UP
Did they do that for the 2a? No. So why would they do it now?
Good article on BP cash over seas and their need to spend because of patent expiration issues.
http://www.fiercepharma.com/pharma/which-drugmakers-have-biggest-overseas-cash-coffers-amgen-and-gilead-to-name-a-couple
Update on B-UP
So when the stock fell by more than a couple of pionts after the articles by mako who said they were shorting.
..that was what?
No not a theory. They said they were shorting on each of their articles which contained to many lies to count.
Most of that was done by MAKO spreading lies for their own shorting purposes.
Did you not seeing the filing! Oh by the way it was voluntary.
Thanks this is very good information.
I would imagine it sold off because the traders weren't given the news they wanted. The P trial is taking longer but they have increased the number of locations. Part of doing trials.
So today we got a voluntary filing from Aruda which basically told the whole world he hasn't sold much of his free shares of ctix. To me that is great news. I won't speculate why he hasn't sold but I think it's good news for us longs.
Well said! Thank you
Couldn't agree more. And it takes away a huge argument from the manipulators.
"It seems obvious that he has been aware of how his rate of disposition could affect the share" seems like another assumption on your part. You have no idea why he is selling or not selling.
Mods please sticky! Awesome
Or who paid for the 2nd mako piece? Maybe you know?
How the hell do you know which trial of ours is the most promising? P and B-OM will be done soon enough and each of these could be moved forward very quickly and cost effectively.
My thought exactly!
Do you think B-OM could be used for other cancers other than head and neck? Many people who undergo chemo or radiation develop om. I know that they chose head and neck because om occurs in a very high percentage but it seems to me the market could be much larger than head and neck patients even if it was used in a off label manner.
Sweet! Do I get a prize?
Great article on BP patent problems.
http://www.fiercepharma.com/pharma/big-pharma-faces-26-5b-patent-loss-threats-year-analyst-says
Remember our 1st goal is partnership. The BP are desperate for new drugs/revenue. Most have significant patent expiration problems in the next 2 or 3 years.
There were only 330 granted in 2016.
They would look at the potential revenue of the drug and the management's ability to get drugs through trials successfully. What else is there? $$$
Please review:
Trying reading this post by Justfactsman again:
several observations...ultimately supporting Karin's observations on Dr. Menon
1. No one disputes that it did appear in originally in a filing ... (assuming it is correct, because I am not going to check the SEC filing , ie original sources...which is how mistakes are made and innocently perpetuated)... and, as you note, was continued.
2. All your previous posts on the subject (2015) are "secondary references"...meaning they are not original sources, i.e. the filings, but rather publications that picked up the inaccuracy in the original 10-K in 2008 (or 2007) and repeating them. You then repeat the repeats. You well know all your references alluding to Dr. Menon "repeating" are other's repeating.
3. It is virtually impossible to correct, if any, "ORIGINAL SOURCE" materials that have inaccurate statements or factual inaccuracies in that document, once filed, since they are part of the original "record". This is especially true of one filed with SEC. You can file an amendment...but the original remains. You can supplement with retractions and corrections is separate docs. As long as it remains in the original doc it can and generally will be inaccurately cited by those in whom the inaccuracy benefits. (and ignore corrections in the record!)
4. HERE IS THE REALITY...most of the time, (and 90% of the time with a Pink Sheet / BB company), the CEO executing the 10K (or filed doc) relies on the attorney who is preparing the document being filed to have assembled and checked the doc for factual accuracy. THEY DONT READ IT!
The smaller, less business/legal sophistication...the more likely it won't be read, but "relied upon". And a Doctor is going to read all these non-Medical docs which he knows absolutely nothing about? Highly unlikely at that business level.
(The attorney will have a secretary, para-legal or associate reviewing whatever bio's might have been provided to read them, and lift the important info and insert in doc. Someone down the food chain, likely read Dr. Menon's vita/bio, saw "collaborating in study at Harvard" "pursuing his PHD"...and bam...mistake is made. Then goes up the food chain with: "did you check this"...answer "Yes"...end of story)
5. Once on the internet, always on the internet...enough said. Those who want to prey on the original mistake will do so until the cows come home. (dating myself)
6. Horrified or Doubt individuals don't read legal docs before signing and rely upon attorneys/preparers to reflect accuracy of content? 98% of congressmen don't read the bills they sign off on...they rely on drafters Telling them what it says...they do not read it first hand (unless they sponsored it...and we hope). I point to as proof, (as well as knowing congressional staff) the infamous bimbo's statement: "We have to pass it to find out what is in it" (Nancy Pelosi)
7. Finally, not looking, (not going to put more time into this) Dr. Menon likely did not sign the 10K, he wasn't CEO. But whomever did...all above applies.
At this point...IMHO...it is beyond necessary to further discuss...if you want to assign an intent or nefarious reason for the original mistake...be my guest.
PS. ...My comments are based upon 42 years of personal experience as an attorney in areas of business/contract/corporate, bankruptcy and SEC law...as well as having been a Chairman/CEO a public (BB) company, dealing with these issues on the other side. My opinions are my own...but based upon real experience...not "in theory".